Evidence map›Paper›PMID 39821662›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Clinical impact of an explainable machine learning with amino acid PET imaging: application to the diagnosis of aggressive glioma.

Shamimeh Ahrari, Timothée Zaragori, Adeline Zinsz, Gabriela Hossu, Julien Oster, Bastien Allard, Laure Al Mansour, Darejan Bessac, Sami Boumedine, Caroline Bund and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Reducing acquisition time in O-(2-Quantitative imaging in medicine and surgery · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shamimeh AhrariIADI, U1254, Inserm, Université de Lorraine, Nancy, France. shamimeh.ahrari@univ-lorraine.fr.ORCID 0000-0003-0422-5808
Timothée ZaragoriIADI, U1254, Inserm, Université de Lorraine, Nancy, France.
Adeline ZinszDepartment of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
Gabriela HossuIADI, U1254, Inserm, Université de Lorraine, Nancy, France.
Julien OsterIADI, U1254, Inserm, Université de Lorraine, Nancy, France.
Bastien AllardDepartment of Nuclear Medicine, Centre Hospitalier de Valence, Valence, France.
Laure Al MansourDepartment of Nuclear Medicine, Hospices Civils de Lyon, Lyon, France.
Darejan BessacDepartment of Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg, France.
Sami BoumedineDepartment of Nuclear Medicine, Centre Antoine Lacassagne, Nice, France.
Caroline BundDepartment of Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg, France.
Nicolas De LeirisDepartment of Nuclear Medicine, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Anthime FlausDepartment of Nuclear Medicine, Hospices Civils de Lyon, Lyon, France.
Eric GuedjDepartment of Nuclear Medicine, Timone Hospital, Marseille, France.
Aurélie KasDepartment of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Nathalie KeromnesDepartment of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Brest, INSERM, UMR 1304, GETBO, University of Western Brittany (UBO), Brest, France.
Kevin KirazDepartment of Nuclear Medicine, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Fiene Marie KuijperDepartment of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Valentine MaitreDepartment of Nuclear Medicine, Timone Hospital, Marseille, France.
Solène QuerellouDepartment of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Brest, INSERM, UMR 1304, GETBO, University of Western Brittany (UBO), Brest, France.
Guilhem StienDepartment of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
Olivier HumbertDepartment of Nuclear Medicine, Centre Antoine Lacassagne, Nice, France.
Laetitia ImbertIADI, U1254, Inserm, Université de Lorraine, Nancy, France.
Antoine VergerIADI, U1254, Inserm, Université de Lorraine, Nancy, France. a.verger@chru-nancy.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadiomics-based machine learning (ML) models of amino acid positron emission tomography (PET) images have shown efficiency in glioma prediction tasks. However, their clinical impact on physician interpretation remains limited. This study investigated whether an explainable radiomics model modifies nuclear physicians' assessment of glioma aggressiveness at diagnosis.

methodsPatients underwent dynamic 6-[

resultsEighty-five patients (54[39-62] years old, 41 women) were selected. In the second phase, physicians demonstrated a significant improvement in diagnostic accuracy compared to the first phase (0.775 [0.750-0.802] vs. 0.717 [0.694-0.737], p = 0.007). The explainable radiomics model augmented physician agreement, with a 22.72% increase in Fleiss's kappa, and significantly enhanced physician confidence (p < 0.001). Among all physicians, Anchor and SHAP showed efficacy in 75% and 72% of cases, respectively, outperforming LIME (p ≤ 0.001).

conclusionsOur results highlight the potential of an explainable radiomics model using amino acid PET scans as a diagnostic support to assist physicians in identifying glioma aggressiveness.

Indexed as

Amino AcidsBrain NeoplasmsGliomaMachine LearningPositron-Emission TomographyAdultAgedDihydroxyphenylalanineFemaleHumansImage Processing, Computer-AssistedMaleMiddle AgedAmino AcidsDihydroxyphenylalaninefluorodopa F 18Explainable machine learningGliomaInterpretabilityPositron emission tomographyRadiomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.